Spectra Intelligence

... Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities ...  |  more...

... have applied themselves to the challenge of entering Western markets with great success. These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger ...  |  more...

... on preclinical scientific studies and expert opinion. In the report, analysts decode the necessary parameters of market success for novel and next-generation drug targets. Through their diligent market research and academic insight, founded on years ...  |  more...

... £1 billion (US$1.8 billion). Importing drugs into the UK is highly attractive for several reasons: The relatively high prices of domestically supplied drugs compared with European counterparts Government incentives encouraging pharmacists to source and dispense ...  |  more...

... medical attention to restore, alter, or improve undesired aspects of body image, physical function, or wellbeing. The conditions are wide-ranging and comprise the four major medical specialty areas of dermatology, psychiatry, reproductive health and sexual ...  |  more...

... global market estimated at US$4.3 billion and forecast to increase 158% to US$11 billion by 2012, drugs for sleep-wake disorders such as insomnia, excessive daytime sleepiness, shift-work sleep disorder, sleep apnoea, and restless legs syndrome ...  |  more...

... discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified ...  |  more...